- Home
- 应用程序分析
- Fitzpatricks Atlas/Synopsis 9E
- Fitzpatricks Atlas/Synopsis 9E Vs. Cancer Survivorship Algorithms
Fitzpatricks Atlas/Synopsis 9E 对比 Cancer Survivorship Algorithms 的使用情况和统计数据
A Doody's Core Title for 2023!
The bestselling, go-to guide to the dermatologic conditions most often encountered in primary care—updated to reflect the latest developments in the field
For more than three decades, Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology has remained one of the bestselling dermatology books in the world. This concise, quick-reference guide has virtually defined the field for thousands of physicians, dermatology residents, and medical students. Covering the most essential content on skin problems, this updated ninth edition combines laser-precise color images of skin lesions along with an overview of epidemiology and pathophysiology, and detailed information on diagnosis and treatment.
Features:
• Extensively revised and expanded with new material
• Complete update of etiology, pathogenesis, management, and therapy
• Over 1,000 full-color images
• Color-coded 4-part organization facilitates review at a glance
• ICD-10 codes are included for each disease
• Many images highlight skin disease in different ethnic populations
No Internet connection needed to view the app after it has been downloaded. It is all ready for quick image and information retrieval. This app is optimized for whatever size device you are using, either phone or tablet.
This app is easy to navigate, allowing you to browse the contents or search for topics. The search tool shows you suggestions that appear in the text as you type so it is quick and helps with spelling medical terms. It also remembers past search terms so you can go back to a topic or image very easily. You can also create notes and bookmarks separately for chapters, images and tables to enhance your learning. You can also change the text size for easier reading.
This interactive app is based on the full content of Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, Ninth Edition by McGraw-Hill Education.
Editors:
Arturo P. Saavedra, MD, PhD, MBA
Ellen K. Roh, MD
Anar Mikailov, MD
Disclaimer: This app is intended for the education of healthcare professionals and not as a diagnostic and treatment reference for the general population.
Developed by Usatine Media, LLC
Richard P. Usatine, MD, Co-President, Professor of Family & Community Medicine, Professor of Dermatology and Cutaneous Surgery, University of Texas Health Science Center San Antonio
Peter Erickson, Co-President, Lead Software Developer
- Apple 应用商店
- 付费
- 医疗
商店排名
- -
Survivorship algorithms depict best practices for care delivery by providing patient management tools to patients under surveillance for cancer recurrence and secondary cancers. Patients are transitioned to Survivorship once there is no evidence of disease for a specific time period dependent on the patient’s cancer site. These algorithms are not intended to replace the independent medical judgment of the physician in the context of individual clinical circumstances to determine a patient's care.
Disclaimer: These algorithms have been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure,
and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to
determine a patient's care. This algorithm should not be used to treat pregnant women.
- Apple 应用商店
- 免费
- 健康与健身
商店排名
- -
Fitzpatricks Atlas/Synopsis 9E与Cancer Survivorship Algorithms排名比较
对比 Fitzpatricks Atlas/Synopsis 9E 与 Cancer Survivorship Algorithms 在过去 28 天内的排名趋势
排名
没有可用的数据
Fitzpatricks Atlas/Synopsis 9E 对比 Cancer Survivorship Algorithms 的排名,按国家/地区比较
对比 Fitzpatricks Atlas/Synopsis 9E 与 Cancer Survivorship Algorithms 在过去 28 天内的排名趋势
无数据可显示
通过免费试用版比较任何网站
Fitzpatricks Atlas/Synopsis 9E VS.
Cancer Survivorship Algorithms
十二月 31, 2024